The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
Genes · 24.02.2023 · 14 (3) · 575
DOI: 10.3390/genes14030575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 24.02.2023. Verfasst von Evgeniya G Poltavskaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia. Hauptthemen laut MEDLINE: Schizophrenia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Background
Personal variations in genetic risk for schizophrenia relate to its phenotypic heterogeneity—both in disorder development and clinical manifestations. Abnormal glutamatergic neurotransmitter system functioning is integrated in the pathogenesis of schizophrenia.
Methods
A sample of 805 Russian schizophrenia patients from the Siberian Federal region was investigated. We examined the association of 39 single nucleotide polymorphisms in eight genes (GRIN2A, GRIN2B, SLC1A2, SLC1A3, SLC17A7, GRM3, GRM7, and GRM8) involved in the glutamatergic system with the development of clinical heterogeneity of schizophrenia. The MassARRAY Analyzer 4 was used for genotyping.
Results
GRIN2A rs11644461, rs8057394 and GRIN2B rs7313149 are associated with the continuous type of schizophrenia. The GRIN2A rs8057394*G allele is a relative risk factor (p = 0.019) for developing the continuous type of schizophrenia. We found a nominally significant association between negative symptoms of schizophrenia and SLC17A7 rs62126236. The SLC17A7 rs62126236*T allele has a protective effect (p = 0.039) against predominant negative symptoms in schizophrenia. The total Positive and Negative Syndrome Scale (PANSS) scores were significantly associated with GRIN2A rs9788936 after adjusting for multiple testing (p = 0.001).
Conclusions
In this study the contribution of the glutamatergic gene polymorphisms to the clinical heterogeneity of schizophrenia has been demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia.
- Department of Psychiatry, Addictology and Psychotherapy, Siberian State Medical University, 634050 Tomsk, Russia.
- Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634050 Tomsk, Russia.
- School of Biological and Behavioural Sciences, Queen Mary University of London, London E1 4NS, UK.
ORCID-Profile: Elena G Kornetova, Ivan V Pozhidaev, Diana Z Paderina, Nikolay A Bokhan, Svetlana A Ivanova, Olga Y Fedorenko
Förderung
- Russian Science Foundation
Zitieren
APA
Poltavskaya, E. G., Kornetova, E. G., Freidin, M. B., Pozhidaev, I. V., Paderina, D. Z., Bocharova, A. V., Semke, A. V., Bokhan, N. A., Ivanova, S. A., & Fedorenko, O. Y. (2023). The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia. Genes, 14(3), 575. https://doi.org/10.3390/genes14030575
Vancouver
Poltavskaya EG, Kornetova EG, Freidin MB, Pozhidaev IV, Paderina DZ, Bocharova AV, et al. The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia. Genes. 2023;14(3):575. doi:10.3390/genes14030575
BibTeX
@article{Poltavskaya2023,
author = {Poltavskaya, Evgeniya G and Kornetova, Elena G and Freidin, Maxim B and Pozhidaev, Ivan V and Paderina, Diana Z and Bocharova, Anna V and Semke, Arkadiy V and Bokhan, Nikolay A and Ivanova, Svetlana A and Fedorenko, Olga Y},
title = {The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia},
journal = {Genes},
year = {2023},
volume = {14},
number = {3},
pages = {575},
doi = {10.3390/genes14030575}
}
EUVIMED